Veratramine ameliorates pain symptoms in rats with diabetic peripheral neuropathy by inhibiting activation of the SIGMAR1-NMDAR pathway

Abstract Context Veratramine may have a potential therapeutic effect for diabetic peripheral neuropathy (DPN). Objective To evaluate whether veratramine ameliorates neuropathic pain in a rat diabetic model. Materials and methods Sprague–Dawley rats were used for a diabetic model induced by a streptozotocin + high-fat diet. Two months after the induction of the diabetic model, the rats with DPN were screened according to the mechanical pain threshold. The rats with DPN were divided into a model group (n = 12) and a treated group (n = 12). Rats with diabetes, but without peripheral neuropathy, were used in the vehicle group (n = 9). The treatment group received 50 μg/kg veratramine via the tail vein once a day for 4 weeks. During modelling and treatment, rats in all three groups were fed a high-fat diet. Results The mechanical withdrawal threshold increased from 7.5 ± 1.9 N to 17.9 ± 2.6 N in DPN rats treated with veratramine. The tolerance time of the treated group to hot and cold ectopic pain increased from 11.8 ± 4.2 s and 3.4 ± 0.8 s to 20.4 ± 4.1 s and 5.9 ± 1.7 s, respectively. Veratramine effectively alleviated L4-L5 spinal cord and sciatic nerve pathological injury. Veratramine inhibited the expression of SIGMAR1 and the phosphorylation of the N-methyl-d-aspartate receptor (NMDAR) Ser896 site in spinal cord tissue, as well as inhibited the formation of SIGMAR1-NMDAR and NMDAR-CaMKII complexes. Discussion and conclusions Veratramine may alleviate the occurrence of pain symptoms in rats with DPN by inhibiting activation of the SIGMAR1-NMDAR pathway.

[1]  Y. Onetti,et al.  The σ1 Receptor and the HINT1 Protein Control α2δ1 Binding to Glutamate NMDA Receptors: Implications in Neuropathic Pain , 2021, Biomolecules.

[2]  W. Rathmann,et al.  Quantifying the underestimation of projected global diabetes prevalence by the International Diabetes Federation (IDF) Diabetes Atlas , 2021, BMJ Open Diabetes Research & Care.

[3]  Tao Ma,et al.  Quercetin Alleviates Neuropathic Pain in the Rat CCI Model by Mediating AMPK/MAPK Pathway , 2021, Journal of pain research.

[4]  Ankang Li,et al.  Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats , 2020, Scientific Reports.

[5]  Yun-Li Zhao,et al.  Seven new veratramine-type alkaloids with potent analgesic effect from Veratrum taliense. , 2019, Journal of ethnopharmacology.

[6]  E. Selvin,et al.  Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes , 2019, Current Diabetes Reports.

[7]  D. Zamanillo,et al.  Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain , 2019, Front. Pharmacol..

[8]  Shuainan Liu,et al.  Maltol, a food flavor enhancer, attenuates diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. , 2018, Food & function.

[9]  I. Wilkinson,et al.  A new look at painful diabetic neuropathy. , 2018, Diabetes research and clinical practice.

[10]  Jatin Kalita,et al.  Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets , 2018, European journal of pharmacology.

[11]  Y. Yanagawa,et al.  NMDA Receptor Activation Underlies the Loss of Spinal Dorsal Horn Neurons and the Transition to Persistent Pain after Peripheral Nerve Injury , 2018, Cell reports.

[12]  N. Gonçalves,et al.  Peripheral Glial Cells in the Development of Diabetic Neuropathy , 2018, Front. Neurol..

[13]  E. Mayatepek,et al.  NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions , 2017, Diabetes, obesity & metabolism.

[14]  J. Entrena,et al.  Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics. , 2017, Advances in experimental medicine and biology.

[15]  Yun-Li Zhao,et al.  Potent anti-inflammatory and analgesic steroidal alkaloids from Veratrum taliense. , 2016, Journal of ethnopharmacology.

[16]  H. Wei,et al.  Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence , 2016, AAPS Journal.

[17]  R. Malik,et al.  Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions. , 2015, The review of diabetic studies : RDS.

[18]  M. Rodríguez-Muñoz,et al.  The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: Implications in neurological disorders , 2015, Oncotarget.

[19]  J. Vela,et al.  The σ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid Analgesia Under NMDA Receptor Negative Control , 2015, Antioxidants & redox signaling.

[20]  F. Quan,et al.  Serotonergic mechanism of the relieving effect of bee venom acupuncture on oxaliplatin-induced neuropathic cold allodynia in rats , 2014, BMC Complementary and Alternative Medicine.

[21]  A. Verkhratsky,et al.  Calcium signalling in sensory neurones and peripheral glia in the context of diabetic neuropathies. , 2014, Cell calcium.

[22]  A. Jar.  [Animal welfare and the use of laboratory animals in scientific research]. , 2014, Revista Argentina de Microbiología.

[23]  Owen M. McDougal,et al.  Medicinal history of North American Veratrum , 2014, Phytochemistry Reviews.

[24]  D. Zamanillo,et al.  Sigma 1 receptor: a new therapeutic target for pain. , 2013, European journal of pharmacology.

[25]  D. Zamanillo,et al.  Pharmacological properties of S1RA, a new sigma‐1 receptor antagonist that inhibits neuropathic pain and activity‐induced spinal sensitization , 2012, British journal of pharmacology.

[26]  V. Spallone.  Management of Painful Diabetic Neuropathy: Guideline Guidance or Jungle? , 2012, Current Diabetes Reports.

[27]  H. Pan,et al.  Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain , 2011, Expert review of clinical pharmacology.

[28]  S. Buch,et al.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator. , 2010, Trends in pharmacological sciences.

[29]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[30]  D. Zamanillo,et al.  Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. , 2009, Central nervous system agents in medicinal chemistry.

[31]  E. Dirice,et al.  Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. , 2009, Human gene therapy.

[32]  J. Entrena,et al.  Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands , 2008, Current neuropharmacology.

[33]  Suneil K. Kalia,et al.  NMDA receptors in clinical neurology: excitatory times ahead , 2008, The Lancet Neurology.

[34]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[35]  R. Quirion,et al.  Expression of the purported sigma1 (σ1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy , 2000, Journal of Chemical Neuroanatomy.

[36]  I. Guillemain,et al.  Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. , 2000, Neuroscience.

[37]  K. Mikoshiba,et al.  Phosphorylation-dependent Regulation ofN-Methyl-d-aspartate Receptors by Calmodulin* , 1997, The Journal of Biological Chemistry.

[38]  R. Slater.  Purification of RNA , 1992 .

[39]  N. Rakieten,et al.  Studies on the diabetogenic action of streptozotocin (NSC-37917). , 1963, Cancer chemotherapy reports.